164 related articles for article (PubMed ID: 24917554)
1. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
Dossi R; Frapolli R; Di Giandomenico S; Paracchini L; Bozzi F; Brich S; Castiglioni V; Borsotti P; Belotti D; Uboldi S; Sanfilippo R; Erba E; Giavazzi R; Marchini S; Pilotti S; D'Incalci M; Taraboletti G
Int J Cancer; 2015 Feb; 136(3):721-9. PubMed ID: 24917554
[TBL] [Abstract][Full Text] [Related]
2. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
Forni C; Minuzzo M; Virdis E; Tamborini E; Simone M; Tavecchio M; Erba E; Grosso F; Gronchi A; Aman P; Casali P; D'Incalci M; Pilotti S; Mantovani R
Mol Cancer Ther; 2009 Feb; 8(2):449-57. PubMed ID: 19190116
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
[TBL] [Abstract][Full Text] [Related]
6. Mode of action of trabectedin in myxoid liposarcomas.
Di Giandomenico S; Frapolli R; Bello E; Uboldi S; Licandro SA; Marchini S; Beltrame L; Brich S; Mauro V; Tamborini E; Pilotti S; Casali PG; Grosso F; Sanfilippo R; Gronchi A; Mantovani R; Gatta R; Galmarini CM; Sousa-Faro JM; D'Incalci M
Oncogene; 2014 Oct; 33(44):5201-10. PubMed ID: 24213580
[TBL] [Abstract][Full Text] [Related]
7. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
Frapolli R; Tamborini E; Virdis E; Bello E; Tarantino E; Marchini S; Grosso F; Sanfilippo R; Gronchi A; Tercero JC; Peloso G; Casali P; Pilotti S; D'Incalci M
Clin Cancer Res; 2010 Oct; 16(20):4958-67. PubMed ID: 20732964
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
D'Incalci M; Badri N; Galmarini CM; Allavena P
Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
[TBL] [Abstract][Full Text] [Related]
9. The intriguing patterns of tumor response to trabectedin.
Sanfilippo R; Casali PG
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
[TBL] [Abstract][Full Text] [Related]
11. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells.
Atmaca H; Uzunoglu S
Eur Cytokine Netw; 2014 Mar; 25(1):1-7. PubMed ID: 24941346
[TBL] [Abstract][Full Text] [Related]
13. PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.
Charytonowicz E; Terry M; Coakley K; Telis L; Remotti F; Cordon-Cardo C; Taub RN; Matushansky I
J Clin Invest; 2012 Mar; 122(3):886-98. PubMed ID: 22293175
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
Assi T; Kattan J; El Rassy E; Honore C; Dumont S; Mir O; Le Cesne A
Cancer Treat Rev; 2019 Jan; 72():37-44. PubMed ID: 30468937
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.
Nakai T; Imura Y; Tamiya H; Yamada S; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Cancer Med; 2017 Sep; 6(9):2121-2130. PubMed ID: 28745431
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
Grosso F; Sanfilippo R; Virdis E; Piovesan C; Collini P; Dileo P; Morosi C; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2009 Aug; 20(8):1439-44. PubMed ID: 19465423
[TBL] [Abstract][Full Text] [Related]
17. Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
Frapolli R; Bello E; Ponzo M; Craparotta I; Mannarino L; Ballabio S; Marchini S; Carrassa L; Ubezio P; Porcu L; Brich S; Sanfilippo R; Casali PG; Gronchi A; Pilotti S; D'Incalci M
Clin Cancer Res; 2019 Dec; 25(24):7565-7575. PubMed ID: 31481505
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
Bello E; Brich S; Craparotta I; Mannarino L; Ballabio S; Gatta R; Marchini S; Carrassa L; Matteo C; Sanfilippo R; Gronchi A; Casali PG; Pilotti S; D'Incalci M; Frapolli R
Br J Cancer; 2019 Sep; 121(6):464-473. PubMed ID: 31409911
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
Saponara M; Stacchiotti S; Gronchi A
Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
Gronchi A; Bui BN; Bonvalot S; Pilotti S; Ferrari S; Hohenberger P; Hohl RJ; Demetri GD; Le Cesne A; Lardelli P; Pérez I; Nieto A; Tercero JC; Alfaro V; Tamborini E; Blay JY
Ann Oncol; 2012 Mar; 23(3):771-776. PubMed ID: 21642514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
